Tizanidina 4 mg

Descrizione Del Prodotto

1. Classification and Chemical Overview

Tizanidine 4mg is a licensed branded and generic oral pharmaceutical preparation (originally developed and commercialized under innovator trade names such as Zanaflex). Chemically designated as $5\text{-chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-2,1,3-benzothiadiazol-4-amine}$, tizanidine is an imidazoline-containing derivative belonging to the centrally acting skeletal muscle relaxant and $\alpha_2$-adrenergic agonist chemical classes. Structurally, it consists of a planar 2,1,3-benzothiadiazole nucleus substituted with a chlorine atom at carbon-5 and an imidazoline-2-ylamino moiety at carbon-4. It exhibits structural homology to the prototypical antihypertensive imidazoline clonidine, but possesses distinct pharmacodynamic modifications that optimize its selectivity for spinal polysynaptic reflexes over peripheral cardiovascular tone. Its empirical molecular formula is $\text{C}_9\text{H}_8\text{ClN}_5\text{S}$, with an average molecular weight of $253.71\text{ g/mol}$ (formulated as the hydrochloride salt: $\text{C}_9\text{H}_8\text{ClN}_5\text{S}\cdot\text{HCl}$, molecular weight $290.17\text{ g/mol}$).

Standard solid oral presentations of Tizanidine 4mg in the United Kingdom appear as round, white to off-white, flat or biconvex compressed scored tablets. Tablets characteristically feature a cross-score or bisecting line on one face to allow division into equal halves ($2\text{ mg}$) or quarters ($1\text{ mg}$) to facilitate precise titration. Standard non-active pharmaceutical excipients include anhydrous lactose, microcrystalline cellulose, colloidal anhydrous silica, and stearic acid.

Within the United Kingdom regulatory framework:

• Medicinal Classification: Tizanidine 4mg is categorized as a Prescription Only Medicine (POM) governed by the Human Medicines Regulations 2012. It is catalogued in the British National Formulary (BNF) and listed on the NHS Drug Tariff, making it reimbursable across NHS primary and secondary care prescription pathways (FP10).

• Controlled Drug Status: Tizanidine is not a controlled substance under the Misuse of Drugs Act 1971 or the Misuse of Drugs Regulations 2001.

While tizanidine lacks classical primary euphoric liability, it is occasionally misused off-label or co-ingested in polydrug scenarios to augment the sedative and dissociative effects of opioids, benzodiazepines, or alcohol. In clinical and toxicology practice, its most critical risks stem from severe, life-threatening pharmacokinetic interactions with potent CYP1A2 inhibitors (which trigger profound hypotension, bradycardia, and coma), unmonitored hepatotoxicity, and severe rebound hypertensive crises upon abrupt cessation.

2. Mechanism of Action and Pharmacodynamics

The pharmacodynamic profile of tizanidine is defined by potent, selective agonism of central presynaptic $\alpha_2$-adrenergic receptors within the spinal cord and brainstem:

• Centrally Acting $\alpha_2$-Adrenoceptor Agonism: Tizanidine binds with high stereospecific affinity to presynaptic $\alpha_2$-adrenoceptors localized predominantly in the superficial dorsal horn, intermediate gray matter, and motor neuronal networks of the spinal cord:

  • Agonism of $\alpha_2$ receptors couples to pertussis toxin-sensitive inhibitory $G_{\alpha i/o}$ proteins. This suppresses adenylate cyclase activity, reduces intracellular cyclic adenosine monophosphate (cAMP), blunts presynaptic voltage-gated N-type calcium ($Ca^{2+}$) influx, and activates inwardly rectifying potassium ($K^+$) conductances.

  • Inhibition of Excitatory Neurotransmitter Release: The cellular consequence is the direct, profound suppression of the release of excitatory amino acids—specifically L-glutamate and L-aspartate—from interneurons in the spinal cord.

• Depression of Spinal Polysynaptic Reflexes: By blunting excitatory glutamatergic signaling, tizanidine suppresses spinal polysynaptic reflex pathways that mediate skeletal muscle hypertonia, spasms, and clonus. Monosynaptic spinal stretch reflexes (such as the knee-jerk reflex) are only weakly or minimally affected at therapeutic concentrations.

• Attenuation of Facilitatory Interneurons (Locus Coeruleus Downregulation): Beyond direct spinal action, tizanidine reduces the firing rate of noradrenergic neurons in the locus coeruleus, dampening descending facilitatory bulbospinal noradrenergic pathways that normally drive motor neuronal hyper-excitability.

• Separation of Antispastic and Cardiovascular Profiles: While structurally an imidazoline analogue of clonidine, tizanidine exhibits a relatively favorable separation of motor antispasticity from systemic vasodepression. It displays approximately one-tenth to one-fifteenth of the antihypertensive potency of clonidine. Nevertheless, because it retains central and peripheral $\alpha_2$-agonist activity, clinically significant decreases in blood pressure (systolic and diastolic drops of $20\text{ to }30\text{ mmHg}$) and reductions in heart rate occur, particularly at doses $\ge 4\text{ to }8\text{ mg}$ or during rapid upward titration.

• Lack of Direct Neuromuscular Junction Action: Tizanidine exerts no direct action on the neuromuscular junction (NMJ), acetylcholine release, or the contractile machinery of skeletal muscle fibers, preserving baseline voluntary muscle strength significantly better than direct-acting agents like dantrolene.

3. Approved UK Clinical Indications and Therapeutic Scope

Tizanidine 4mg holds narrow, specialist-directed clinical indications in the United Kingdom under BNF and National Institute for Health and Care Excellence (NICE) guidelines:

• Spasticity Associated with Multiple Sclerosis (MS):

  • Indicated for the symptomatic management of chronic spasticity, painful muscle spasms, and clonus secondary to multiple sclerosis. Evaluated in NICE Guideline NG220 (Multiple sclerosis in adults), where tizanidine is positioned alongside oral baclofen and gabapentin as a first-line or second-line pharmacological option to improve mobility, facilitate nursing care, and alleviate pain from muscle contractures.

• Spasticity Associated with Spinal Cord Injury or Disease:

  • Indicated for the reduction of skeletal muscle hypertonia resulting from traumatic spinal cord transection, spinal cord injury, myelopathy, syringomyelia, or degenerative spinal disorders.

• Spasticity Resulting from Cerebrovascular Accidents (Stroke):

  • Adjunctive management of upper motor neuron spasticity following ischaemic or haemorrhagic stroke or in adult cerebral palsy, helping patients engage in physical neurorehabilitation and physiotherapy.

Clinical Dosing and Titration Strategy

Because of marked inter-individual pharmacokinetic variability and high sensitivity to sedation and hypotension, treatment must be initiated at low doses and titrated gradually:

• Initial Titration: Initiated at a single daily dose of $2\text{ mg}$ (half of a 4mg tablet), taken at bedtime to mitigate daytime sedation.

• Escalation: Dose is titrated upwards in increments of $2\text{ mg}$ every 3 to 4 days, dividing administrations into three to four doses per day according to individual spasticity patterns and physical activity requirements.

• Standard Daily Range: The usual therapeutic range is $12\text{ to }24\text{ mg}$ daily in 3 or 4 divided doses.

• Maximum Recommended Ceiling: The total daily dose must never exceed $36\text{ mg}$ in 24 hours, and a single individual dose should not exceed $12\text{ mg}$, due to steep, non-linear escalations in somnolence, cardiovascular collapse, and liver enzyme elevations.

In non-clinical or unauthorized contexts, tizanidine is sometimes acquired through diversion or online sources to self-manage acute, painful musculoskeletal conditions (e.g., severe mechanical lower back spasm, whiplash), off-label insomnia, or to potentiate the depressive effects of opioids.

4. Pharmacokinetic Profile and Metabolic Fate

The pharmacokinetic profile of tizanidine is characterized by rapid oral absorption, extensive first-pass hepatic extraction, and near-exclusive reliance on cytochrome P450 1A2 (CYP1A2) for metabolic clearance:

• Absorption: Following oral administration, tizanidine is absorbed rapidly and almost completely across the gastrointestinal tract. Peak plasma concentrations ($C_{max}$) are achieved within 1 to 2 hours (median $T_{max} \approx 1.0\text{ hour}$). However, absolute oral bioavailability is remarkably low, averaging approximately $34\%$ (range: $20\text{ to }40\%$) due to intense, saturable hepatic first-pass metabolism. Co-administration with food alters absorption: food increases $C_{max}$ by approximately $30\%$ and shortens $T_{max}$, which can subtly intensify transient sedative and hypotensive peaks; tablets should be taken consistently with or without food.

• Distribution: Tizanidine displays moderate lipophilicity, penetrating the blood-brain barrier rapidly to access spinal and central $\alpha_2$-adrenergic receptors. It possesses an apparent steady-state volume of distribution ($V_{ss}$) of approximately $2.4\text{ to }2.6\text{ L/kg}$. In circulating human plasma, tizanidine displays low plasma protein binding (approximately $30\%$ bound), binding non-specifically to human serum albumin. It crosses the placenta and is excreted into maternal breast milk in animal models.

• Biotransformation (The CYP1A2 Monopoly): Systemic clearance is mediated almost entirely ($>95\%$) through hepatic microsomal oxidative metabolism catalyzed almost exclusively by the cytochrome P450 1A2 (CYP1A2) isoenzyme:

  • CYP1A2 oxidizes the imidazoline and benzothiadiazole rings, forming inactive, cleaved, and hydroxylated metabolites.

  • None of the primary circulating hepatic metabolites possess biologically meaningful $\alpha_2$-adrenergic agonist or antispastic activity.

  • Critical Clinical Vulnerability: Because tizanidine relies nearly exclusively on a single enzyme pathway with low baseline bioavailability, any inhibition of CYP1A2 leads to dramatic, catastrophic spikes in circulating unmetabolized drug, transforming a standard $4\text{ mg}$ dose into a toxic, life-threatening overdose.

• Elimination: Systemic elimination is predominantly renal. Approximately $70\%$ of an administered radioactive dose is recovered in the urine as polar, inactive metabolites within 72 hours; approximately $20\%$ is excreted in the faeces. Less than $3\%$ of parent drug is excreted unchanged in the urine.

  • The terminal elimination plasma half-life ($t_{1/2}$) of tizanidine is exceptionally short, averaging $2\text{ to }4\text{ hours}$.

  • Because of this short half-life, the antispastic duration of a single dose lasts only 3 to 6 hours. This mandates frequent divided daily dosing (TDS or QDS) to maintain smooth spasticity control throughout waking hours.

5. Physiological Effects and Adverse Event Spectrum

The primary physiological effect in authorized clinical practice is a rapid reduction in muscle tone, resistance to passive stretch, and suppression of painful spasms. However, central $\alpha_2$ agonism and systemic vasodepression generate an extensive adverse event profile:

• Central Nervous System Depression (Very Common, $\ge 1/10$):

  • Profound Somnolence and Sedation: Occurs in up to $40\text{ to }50\%$ of treated individuals. Typically peaks 1 to 2 hours post-dose (coinciding with $C_{max}$) and can severely impair motor coordination, alertness, and driving capabilities.

  • Dizziness, fatigue, lightheadedness, and cognitive slowing.

  • Hallucinations and Delirium: Visual and auditory hallucinations, confusional states, and vivid dreams (reported in $1\text{ to }3\%$ of patients, resolving within days of drug withdrawal).

  • Muscle weakness and flaccidity: Reductions in spastic tone can compromise the “functional spasticity” that some patients with severe paresis rely on to stand, transfer, or ambulate.

• Cardiovascular Dysregulation (Common, $1/100$ to $<1/10$):

  • Clinically Significant Arterial Hypotension: Marked reductions in systolic and diastolic blood pressure. Peak hypotensive actions manifest 2 to 3 hours post-ingestion.

  • Postural (orthostatic) hypotension and syncope.

  • Bradycardia: Decreased central sympathetic outflow lowers heart rate, occasionally causing sinus bradycardia ($<50\text{ bpm}$) and conduction delays.

  • Cardiac QTc Prolongation: Tizanidine causes concentration-dependent prolongation of the cardiac QTc interval, conferring pro-arrhythmic liabilities at elevated plasma levels or in overdose.

• Gastrointestinal and Autonomic Effects:

  • Xerostomia (dry mouth): Reported in up to $50\%$ of patients due to central and peripheral muscarinic/adrenergic modulation.

  • Gastrointestinal disturbances: Nausea, epigastric discomfort, dyspepsia, and constipation.

• Severe, Emergent and Organ Toxicities (Rare to Critical Hazards):

  • Hepatotoxicity and Liver Injury: Tizanidine is a recognized cause of clinically significant hepatocellular injury. Asymptomatic, reversible elevations in serum transaminases (ALT, AST) exceeding three times the upper limit of normal occur in up to $5\%$ of treated patients. Rare cases of severe acute hepatitis, jaundice, liver failure, and death have been documented, typically manifesting within the first 1 to 6 months of initiation.

  • Abrupt Discontinuation Crisis (Rebound Hypertension and Tachycardia): Following chronic administration, sudden cessation triggers an acute withdrawal syndrome:

    • Rebound, malignant arterial hypertension.

    • Severe sinus tachycardia and palpitations.

    • Hypertonia, muscle rigidity, tremors, unremitting spasticity storms, and acute psychomotor agitation.

    • In high-dose chronic users, withdrawal can trigger catastrophic hypertensive encephalopathy and cerebrovascular accidents (stroke).

  • Synergistic Central Nervous System Collapse: Co-ingestion with other central depressants (e.g., opioids, alcohol, benzodiazepines) leads to profound central hypoventilation, airway compromise, unarousable coma, and death.

6. Contraindications, Drug Interactions, and Clinical Precautions

Prescribing, titrating, and monitoring Tizanidine 4mg requires strict adherence to absolute drug-interaction exclusions, biochemical monitoring intervals, and withdrawal prevention protocols:

• Contraindications:

  • Concomitant Fluvoxamine or Ciprofloxacin: Absolute, Life-Threatening Contraindication. Co-administration with strong CYP1A2 inhibitors is strictly prohibited.

  • Severe Hepatic Impairment: Absolute contraindication in severe liver disease, acute hepatitis, or unexplained, persistent baseline transaminase elevations ($>3 \times \text{ULN}$), due to impaired clearance and high intrinsic hepatotoxicity risk.

  • Hypersensitivity: Hypersensitivity to tizanidine base or formulation excipients.

  • Severe Renal Failure: Used with extreme caution and reduced dosing in renal impairment (creatinine clearance $<25\text{ mL/min}$); clearance is decreased by more than $50\%$, elevating exposure and toxic accumulation.

  • Pregnancy and Lactation: Contraindicated during pregnancy unless benefits clearly outweigh risks (crosses the placenta, causes embryo-fetal toxicity and developmental arrest in animal studies); contraindicated in nursing mothers (distributes into breast milk).

  • Paediatric Population: Contraindicated in children and adolescents under 18 years of age due to lack of safety data.

• Drug Interactions:

  • Potent Cytochrome P450 1A2 Inhibitors (e.g., Ciprofloxacin, Fluvoxamine): Absolute Contraindication.

    • Fluvoxamine increases tizanidine plasma concentrations ($AUC$) by $33\text{-fold}$ and increases $C_{max}$ by $12\text{-fold}$.

    • Ciprofloxacin increases tizanidine $AUC$ by $10\text{-fold}$ e $C_{max}$ by $7\text{-fold}$.

    • These combinations induce catastrophic clinical toxicity: profound, prolonged coma, unresponsiveness, severe refractory hypotension, bradycardia, and respiratory arrest.

  • Other CYP1A2 Inhibitors (e.g., Enoxacin, Zileuton, Amiodarone, Mexiletine, Propafenone, Oral Contraceptives, Cimetidine, Ticlopidine): Moderate-to-weak inhibitors significantly increase tizanidine exposure (oral contraceptives can increase exposure by up to $50\%$). Co-administration must be strictly avoided or undertaken with extreme dosage reduction and hemodynamic monitoring.

  • Antihypertensive Agents and Diuretics: Synergistic hypotensive and bradycardic interactions; requires close blood pressure surveillance.

  • Central Nervous System Depressants (e.g., Opioids, Benzodiazepines, Alcohol, Sedating Antihistamines): Synergistic amplification of somnolence, motor ataxia, respiratory depression, and cognitive impairment.

  • QTc-Prolonging Drugs (e.g., Haloperidol, Methadone, Erythromycin, Sotalol): Additive prolongation of the ventricular repolarization interval, predisposing to Torsades de Pointes.

  • Cigarette Smoking (CYP1A2 Induction): Polycyclic aromatic hydrocarbons in tobacco smoke induce CYP1A2, reducing systemic tizanidine exposure by up to $30\text{ to }40\%$, requiring higher doses in heavy smokers.

• Clinical Precautions and Harm Minimisation:

  • Mandatory Liver Function Monitoring Protocol:

    • In accordance with MHRA and BNF directives, baseline Liver Function Tests (LFTs: ALT, AST, Alkaline Phosphatase, Bilirubin) must be measured prior to starting treatment.

    • Monitoring Timeline: LFTs must be monitored monthly for the first 4 months of therapy, and periodically thereafter, or immediately if unexplained nausea, anorexia, fatigue, right upper quadrant pain, or jaundice occurs.

    • Withdrawal Threshold: If serum ALT or AST persistently exceeds $3 \times \text{the upper limit of normal (ULN)}$, tizanidine must be immediately and permanently discontinued.

  • Protocol for Safe Discontinuation (Preventing Rebound Crises):

    • Tizanidine must never be abruptly halted in patients taking maintenance doses $\ge 8\text{ to }12\text{ mg/day}$ or those treated for more than a few days.

    • Doses should be tapered down slowly and systematically (e.g., reducing by $2\text{ to }4\text{ mg}$ per day under regular blood pressure surveillance) to prevent rebound hypertension, severe tachycardia, and hypertonic spasticity crises.

  • Acute Overdose Management (“Red Flags”):

    • Presentations to NHS emergency departments (999/A&E) with tizanidine overdose or CYP1A2 interaction toxicity feature deep stupor/coma, severe hypoventilation, miosis or normal pupils, profound hypotension ($<80/40\text{ mmHg}$), and severe bradycardia ($<40\text{ bpm}$):

      • Airway Support: Secure airway patency, position in the recovery position, provide high-flow oxygen, and provide mechanical ventilation if respiratory depression is present.

      • Hemodynamic Resuscitation: Administer aggressive intravenous volume expansion with balanced crystalloids ($0.9\%$ sodium chloride) to restore intravascular volume.

      • Reversal of Bradycardia and Vasopressor Support: Administer intravenous atropine ($500\text{ mcg}$ to $1\text{ mg}$ IV) for hemodynamically unstable bradycardia. For persistent hypotension refractory to crystalloids, initiate inotropic/vasopressor infusions (e.g., noradrenaline or dopamine).

      • Role of Naloxone: Case reports indicate that high-dose intravenous naloxone ($0.4\text{ to }2\text{ mg}$ IV) may reverse central sedation and hypotension in isolated cases (likely via opioid-adrenergic receptor cross-talk in brainstem pathways), though its efficacy is unpredictable; it may be trialed as an adjunct during unarousable comatose states.

      • Dialysis Ineffectiveness: Due to its extensive volume of distribution ($V_{ss} > 2.4\text{ L/kg}$), hemodialysis is completely ineffective for accelerating drug clearance.

  • Patient Safety Warnings: Patients must be warned of the high risk of sudden, severe somnolence occurring within 1 to 2 hours of ingestion and instructed never to drive, operate machinery, or perform hazardous tasks until their individual response is established. Patients must be explicitly educated never to take tizanidine alongside fluoroquinolone antibiotics (e.g., ciprofloxacin) prescribed for urinary or chest infections.